Alliance Trial Seeks to Improve Standard of Care for Initial Therapy of Older Adults with Chronic Lymphocytic Leukemia

The optimal initial therapy for older adults with chronic lymphocytic leukemia (CLL) has not been established. The drug ibrutinib is a first-in-class, orally-administered, covalently-binding small molecule inhibitor of BTK currently under development for the treatment of B-cell malignancies. Ibrutinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with CLL/small lymphocytic lymphoma (SLL) and Waldenstrom’s Macroglobulinemia and for patients with


UPCOMING MEETINGS

2019 Fall Group Meeting | November 7-9
2020 Group Meetings | May 14-16 + November 5-7
2021 Group Meetings | May 13-15 + November 4-6

Loews Chicago O'Hare Hotel, Rosemont, IL 60018
open to all Alliance members

TWEETS

FROM THE NCI